Immuno-PET using anticarcinoembryonic antigen bispecific antibody and 68Ga-labeled peptide in metastatic medullary thyroid carcinoma: Clinical optimization of the pretargeting parameters in a first-in-human trial

Journal of Nuclear Medicine

Volumn 57, Issue 10, 2016, Pages 1505-1511

  Bodet Milin, Caroline ^a,b   Faivre Chauvet, Alain ^a,b   Carlier, Thomas ^a,b   Rauscher, Aurore ^b,c   Bourgeois, Mickael ^a,b   Cerato, Evelyne ^a   Rohmer, Vincent ^d   Couturier, Olivier ^d   Drui, Delphine ^e   Goldenberg, David M ^f,g   Sharkey, Robert M ^g   Barbet, Jacques ^b,h   Kraeber Bodere, Francoise ^a,b,c  

^a HÔTEL DIEU   (France)

^b CNRS   (France)

^c UMR INSERM U892 CNRS 6299   (France)

^d ANGERS UNIVERSITY HOSPITAL   (France)

^e NANTES UNIVERSITY HOSPITAL   (France)

^f IBC Pharmaceuticals Inc   (United States)

^g IMMUNOMEDICS INC   (United States)

^h GIP Arronax   (France)

Author keywords

68Ga; Bispecific antibody; Immuno PET; Medullary thyroid carcinoma; Pharmacokinetics; Pretargeting

Indexed keywords

6 FLUORODOPA F 18; BISPECIFIC ANTIBODY; GALLIUM 68; IMP 288; IMP 288 GA 68; PEPTIDE DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; RADIOPHARMACEUTICAL AGENT; TF 2; UNCLASSIFIED DRUG; CARCINOEMBRYONIC ANTIGEN; DOTA-TYROSYL-LYSYL(HISTAMINYL-SUCCINYL-GLYCYL)-GLUTAMYL-LYSYL(HISTAMINYL-SUCCINYL-GLYCYL)AMIDE; GALLIUM; OLIGOPEPTIDE; SINGLE HETEROCYCLIC RINGS;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DOSE RESPONSE; DRUG CLEARANCE; DRUG UPTAKE; FEMALE; HUMAN; IMMUNOSCINTIGRAPHY; MALE; MEDIASTINUM; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; THYROID MEDULLARY CARCINOMA; CARCINOMA; CHEMISTRY; IMMUNOLOGY; ISOTOPE LABELING; METABOLISM; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; RADIOIMMUNOASSAY; THYROID TUMOR;

ADULT; AGED; ANTIBODIES, BISPECIFIC; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NEUROENDOCRINE; FEMALE; GALLIUM RADIOISOTOPES; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; ISOTOPE LABELING; MALE; MIDDLE AGED; NEOPLASM METASTASIS; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RADIOIMMUNODETECTION; THYROID NEOPLASMS;

EID: 84991328235     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.116.172221     Document Type: Article

References (23)

1. Machens A, Schneyer U, Holzhausen H-J, Dralle H. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab. 2005;90:2029-2034.
2. Wells SA, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25:567-610.
3. Luster M, Karges W, Zeich K, et al. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid. 2010;20:527-533.
4. 18F-FDG PET/CT in medullary thyroid cancer. J Nucl Med. 2011;52:1855-1863.
5. Oudoux A, Salaun P-Y, Bournaud C, et al. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J Clin Endocrinol Metab. 2007;92:4590-4597.
6. 18F-DOPA PET in recurrent medullary thyroid carcinoma. J Nucl Med. 2012;53:1863-1871.
7. Peltier P, Curtet C, Chatal JF, et al. Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer. J Nucl Med. 1993;34:1267-1273.
8. Barbet J, Peltier P, Bardet S, et al. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody. J Nucl Med. 1998;39:1172-1178.
9. Wu AM. Antibodies and antimatter: the resurgence of immuno-PET. J Nucl Med. 2009;50:2-5.
10. Boerman OC, Oyen WJG. Immuno-PET of cancer: a revival of antibody imaging. J Nucl Med. 2011;52:1171-1172.
11. Rossi EA, Goldenberg DM, Cardillo TM, McBride WJ, Sharkey RM, Chang C-H. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci USA. 2006;103:6841-6846.
12. 124I-labeled hapten-peptide. J Nucl Med. 2006;47:1678-1688.
13. 18F-labeled hapten peptide in mice with human tumor xenografts. Mol Cancer Ther. 2010;9:1019-1027.
14. Schoffelen R, Boerman OC, Goldenberg DM, et al. Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results. Br J Cancer. 2013;109:934-942.
15. Schoffelen R, Woliner-van der Weg W, Visser EP, et al. Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer. Eur J Nucl Med Mol Imaging. 2014;41:1593-1602.
16. 131I-labeled bivalent hapten in a phase I optimization clinical trial. J Nucl Med. 2006;47:247-255.
17. Bodet-Milin C, Ferrer L, Rauscher A, et al. Pharmacokinetics and dosimetry studies for optimization of pretargeted radioimmunotherapy in CEA expressing advanced lung cancer patient. Front Med (Lausanne). 2015;2:84.
18. 18F radiolabeling for PET. J Nucl Med. 2009;50:991-998.
19. 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer. J Nucl Med. 2013;54:1869-1875.
20. Sharkey RM, McBride WJ, Karacay H, et al. A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res. 2003;63:354-363.
21. Andersson M, Johansson L, Minarik D, Leide-Svegborn S, Mattsson S. Effective dose to adult patients from 338 radiopharmaceuticals estimated using ICRP biokinetic data, ICRP/ICRU computational reference phantoms and ICRP 2007 tissue weighting factors. EJNMMI Phys. 2014;1:9.
22. 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87:586-592.
23. 68Ga-labeled affibody molecules. J Nucl Med. 2010;51:892-897.